Procurement Summary
Country : USA
Summary : Developing Humanized Mouse Models for Nnmt and Sult1a1
Deadline : 05 Sep 2023
Other Information
Notice Type : Tender
TOT Ref.No.: 88160241
Document Ref. No. : 75N95023Q00612
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
Description
COMPETITIVECOMBINED SYNOPSIS / SOLICITATION 75N95023Q00612
.TITLE: Developing humanized mouse models for NNMT and SULT1A1
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotations are being requested and a written solicitation will not be issued.
(ii) The solicitation number is 75N95023Q00612 and the solicitation is issued as a request for quotation (RFQ).
This acquisition is for a commercial item and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13 - Simplified Acquisition Procedures and FAR Part 12 - Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.
(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2023-04, effective June 2, 2023.
(iv) The associated NAICS code is 541380 and the Small Business size standard is $19M. This requirement is Full and Open with no set-aside restrictions.
(v) This requirement is for the following services:
Biochemical testing of inhibitors from the NNMT and SUL1A1 projects have shown lower potency towards the human version of the enzyme vs the mouse version in biochemical and cellular assays. This has forced the use of large amounts of compound in animal studies without a true readout of the therapeutic potential in human. Thus, it is imperative that humanized mouse models are developed for dosing to determine the maximum tolerated dose and subsequent doses for PK/PD and efficacy experiments. The preferable approach to generate such humanized mice will be CRISPR knock in technology. See the attached Statement of Work (SOW) for complete requirement details.
(vi) The Government anticipates a period of performance of 12 months from ...
Active Contract Opportunity
Notice ID : 75N95023Q00612
Related Notice
Department/Ind. Agency : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier : NATIONAL INSTITUTES OF HEALTH
Office : NATIONAL INSTITUTES OF HEALTH NIDA
General Information
Contract Opportunity Type: Combined Synopsis/Solicitation (Updated)
All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
Updated Published Date: Aug 31, 2023 10:28 pm EDT
Original Published Date: Aug 25, 2023 04:50 pm EDT
Updated Date Offers Due: Sep 05, 2023 01:00 pm EDT
Original Date Offers Due: Sep 01, 2023 01:00 pm EDT
Inactive Policy: 15 days after date offers due
Updated Inactive Date: Sep 20, 2023
Original Inactive Date: Sep 16, 2023
Initiative: None
Classification
Original Set Aside:
Product Service Code: 6505 - DRUGS AND BIOLOGICALS
NAICS Code: 541380 - Testing Laboratories and Services
Place of Performance: USA
Documents
Tender Notice
Amendment-1-Final.pdf
5-FAR-52.212-5-Jun-2023.pdf
3-FAR-52.204-24-Nov-2021.pdf
2-VAS-Worksheet.pdf
1_-Statement-of-Work.pdf
8-Commitment-to-Protect-Non-Public.pdf
7-Invoicing-Instructions-With-IPP-3-23.pdf
6-FAR_52.212-4_Addendum_Nov_2021.pdf
4-FAR-52.204-26-Oct-2020.pdf